CD4 and neoplasm: Tumor growth control was still observed in the hexatherapy minus OX40+4-1BB and hexatherapy minus Ad-CEA+N-803 groups (figure 2B–E), even though peripheral CD4+ T cell activity was not profound in these cohorts.